Skip to content

US · EWTX · BIOTECHNOLOGY

Edgewise Therapeutics, Inc. (EWTX) intrinsic value and stock valuation

$39.91as of 2026-11-21 · Mkt cap 4.84B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Edgewise Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values EWTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EWTX’s statements →

Edgewise Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boulder, CO 80301 edgewisetx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-167.79M
20192025
Free cash flow
-$-143.82M
20192025
Total equity
$522.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-191.41M-$-158.83M-$-114.36M-$-71.66M-$-43.22M
Net income-$-167.79M-$-133.81M-$-100.16M-$-67.64M-$-42.81M
EPSd-$-1.63M-$-1.45M-$-1.57M-$-1.26M-$-864.85K
Operating cash flow-$-143.82M-$-109.03M-$-91.95M-$-52.63M-$-33.51M
Capital expenditure-$-260K-$-1.31M-$-5.75M-$-5.55M-$-670K
Free cash flow-$-143.82M-$-110.34M-$-97.69M-$-58.18M-$-34.17M
Total assets$552.6M$486.8M$340M$367.1M$285.2M
Total debt$3.99M$4.74M$5.41M$4.41M$0.00
Net debt-$-57.16M-$-36.93M-$-80.68M-$-17.59M-$-15.57M
Total equity$522.3M$459.2M$318.8M$346.7M$274.4M
Cash and short-term investments$530.1M$470.2M$318.4M$352M$280.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$2.27M$0.00$0.00$0.00$0.00
Gross profit-$-2.27M$0.00$0.00$0.00$0.00
Research and development expenses$151.4M$127M$90.9M$54M$32.2M
Selling, general and administrative expenses$40M$31.9M$23.5M$17.6M$11M
Other expenses-$-2.27M$0.00$0.00$0.00$0.00
Operating expenses$189.1M$158.8M$114.4M$71.7M$43.2M
Cost and expenses$191.4M$158.8M$114.4M$71.7M$43.2M
Interest income$23.6M$25M$14.2M$2.66M$400K
Interest expense$0.00$0.00$0.00$4.02M$0.00
Depreciation and amortization$2.27M$2.29M$1.73M$540K$270K
Ebitda-$-165.53M-$-131.52M-$-98.43M-$-63.08M-$-42.54M
Operating income-$-191.41M-$-158.83M-$-114.36M-$-71.66M-$-43.22M
Total other income/expenses, net$23.6M$25M$14.2M$4.02M$400K
Income before tax-$-167.79M-$-133.81M-$-100.16M-$-67.64M-$-42.81M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-167.79M-$-133.81M-$-100.16M-$-67.64M-$-42.81M
Weighted average shares outstanding$102.9M$92.4M$63.7M$53.6M$49.5M
Weighted average diluted shares outstanding$102.9M$92.4M$63.7M$53.6M$49.5M
Balance sheet
20252024202320222021
Cash and short-term investments$530.1M$470.2M$318.4M$352M$280.8M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$543.4M$475.5M$327M$357M$283.8M
Property, plant and equipment, net$9.22M$11.1M$12.7M$9.85M$910K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$9.22M$11.3M$13M$10.1M$1.46M
Total assets$552.6M$486.8M$340M$367.1M$285.2M
Accounts payable$6.01M$5.58M$4.03M$6.11M$3.84M
Short-term debt$1.01M$1M$980K$610K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$27.4M$23.9M$16.8M$16.6M$10.5M
Long-term debt$2.98M$3.74M$4.43M$3.8M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.98M$3.74M$4.43M$3.8M$330K
Capital lease obligations$1.01M$4.74M$5.41M$4.41M$0.00
Total liabilities$30.4M$27.6M$21.2M$20.4M$10.9M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-546.37M-$-378.58M-$-244.76M-$-144.6M-$-76.96M
Accumulated other comprehensive income (loss)$680K$420K$100K-$-1.35M-$-510K
Total equity$522.3M$459.2M$318.8M$346.7M$274.4M
Total investments$469M$428.5M$232.3M$330M$265.2M
Total debt$3.99M$4.74M$5.41M$4.41M$0.00
Net debt-$-57.16M-$-36.93M-$-80.68M-$-17.59M-$-15.57M
Cash flow statement
20252024202320222021
Net income-$-167.79M-$-133.81M-$-100.16M-$-67.64M-$-42.81M
Depreciation and amortization$2.27M$2.29M$1.73M$540K$270K
Stock-based compensation$34.8M$24.7M$17.6M$10.9M$4.4M
Change in working capital-$-5.37M$10.3M-$-1.56M$4.09M$4.63M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$270K$1.74M-$-90K$50K$2.65M
Net cash provided by operating activities-$-143.82M-$-109.03M-$-91.95M-$-52.63M-$-33.51M
Investments in property, plant and equipment-$-260K-$-1.31M-$-5.75M-$-5.55M-$-670K
Acquisitions, net$0.00$0.00$0.00$70K$240K
Net cash used for investing activities-$-32.79M-$-184.66M$102.9M-$-70.58M-$-242.23M
Common stock issued$196.1M$239.2M$52.6M$129.2M$186.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$196.1M$249.3M$53.2M$129.6M$186.4M
Net change in cash$19.5M-$-44.43M$64.1M$6.43M-$-89.35M
Cash at end of period$61.2M$41.7M$86.1M$22M$15.6M
Operating cash flow-$-143.82M-$-109.03M-$-91.95M-$-52.63M-$-33.51M
Capital expenditure-$-260K-$-1.31M-$-5.75M-$-5.55M-$-670K
Free cash flow-$-143.82M-$-110.34M-$-97.69M-$-58.18M-$-34.17M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Edgewise Therapeutics, Inc.

        Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

        CEO
        Kevin Koch
        Employees
        154
        Beta
        0.28

        Explore

        Frequently asked questions

        What is the intrinsic value of Edgewise Therapeutics, Inc. (EWTX)?

        InvestorsCraft does not currently publish an intrinsic value for EWTX. How the IC value is calculated.

        Is EWTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for EWTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.